Primary Hyperoxaluria Type 1 (PH1)

American Society of Nephrology (ASN) 2025

Congress Details

calander6-9 November, 2025 | TX

locationHouston, TX

The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to lumasiran. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].

Oral

Congress Materials

phase3_efficasy
icon Presentation Type
Poster
location icon Location
Houston, TX
icon Title
Final 60-Month Efficacy, Safety, and Kidney Stone Outcomes of a Phase 3 Trial of Lumasiran for Primary Hyperoxaluria Type 1 in Infants and Young Children
Long_term_lumasiran_treatment
icon Presentation Type
Poster
location icon Location
Houston, TX
icon Title
Long-Term Lumasiran Treatment, Kidney Function, and Isolated Kidney Transplant Outcomes in Primary Hyperoxaluria Type 1
Impacts_of_long_term_usage
icon Presentation Type
Poster
location icon Location
Houston, TX
icon Title
Impact of Lumasiran on Long-Term Clinical Outcomes in Primary Hyperoxaluria Type 1 (PH1): a Cohort Simulation Model
primary_hyperoxalaria
icon Presentation Type
Poster
location icon Location
Houston, TX
icon Title
Kidney Survival in Patients with Primary Hyperoxaluria Type 1 Treated with Lumasiran Compared with Historical Controls

Associated Materials

European-Society-for-Paediatric-Nephrology,Athens,Greece-Mobile

Primary Hyperoxaluria Type 1 (PH1)

European Society for Paediatric Nephrology (ESPN) 2025

15-18 October, 2025 Greece

View Details
Preparation Date
March 2026
Job Code
MB-UK-00085
International Paediatric Transplant Association (IPTA) 2025 Congress, Germany

Primary Hyperoxaluria Type 1 (PH1)

International Paediatric Transplant Association (IPTA) 2025

18-21 September 2025 Germany

View Details
Preparation Date
March 2026
Job Code
MB-UK-00088
European Society for Paediatric Urology (ESPU) 2025 Congress, Austria

Primary Hyperoxaluria Type 1 (PH1)

European Society for Paediatric Urology (ESPU) 2025

3-6 September 2025 AUSTRIA

View Details
Preparation Date
March 2026
Job Code
MB-UK-00089
European Society for Paediatric Urology (ESPU) 2025 Congress, Austria

Primary Hyperoxaluria Type 1 (PH1)

European Renal Association (ERA) 2025

4-7 June 2025 Austria

View Details
Preparation Date
March 2026
Job Code
MB-UK-00091

Primary Hyperoxaluria Type 1 (PH1)

Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-Up of the Phase 3 Illuminate-C Trial

American Journal of Kidney Diseases

Author(s)

Anne-Laure Sellier-Leclerc, Daniella Magen, Hadas Shasha-Lavsky, et al

March 2025

Preparation Date
March 2026
Job Code
MB-UK-00171
International Paediatric Nephrology Association (IPNA) 2025 Congress, South Africa

Primary Hyperoxaluria Type 1 (PH1)

International Pediatric Nephrology Association (IPNA) 2025

19-23 February, 2025 SA

View Details
Preparation Date
March 2026
Job Code
MB-UK-00093
Preparation Date
March 2026
Job Code
MB-UK-00086